In summary, all this data support our previous results in NSCLC, suggesting the potential use of MKK6/MKK3 as biomarker in cisplatin based therapy and confirming our proposed model also for HNSCC (Fig. 5). The gene discussed is MAP2K3; the disease is non-small cell lung carcinoma.